Haleon plc (NYSE:HLN) Stock Holdings Decreased by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. trimmed its position in Haleon plc (NYSE:HLN - Free Report) by 83.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,458 shares of the company's stock after selling 339,059 shares during the period. D. E. Shaw & Co. Inc.'s holdings in Haleon were worth $634,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sierra Ocean LLC purchased a new position in shares of Haleon in the 4th quarter valued at about $26,000. Geneos Wealth Management Inc. acquired a new position in Haleon in the 4th quarter valued at about $35,000. Spire Wealth Management acquired a new stake in Haleon during the fourth quarter worth approximately $39,000. FIL Ltd boosted its holdings in shares of Haleon by 45.7% during the fourth quarter. FIL Ltd now owns 4,049 shares of the company's stock worth $39,000 after purchasing an additional 1,270 shares during the last quarter. Finally, Addison Advisors LLC grew its holdings in Haleon by 28.7% in the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock valued at $47,000 after buying an additional 1,106 shares during the period. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Performance

Shares of HLN traded up $0.08 during trading hours on Thursday, reaching $11.33. 19,219,066 shares of the company's stock traded hands, compared to its average volume of 8,398,989. Haleon plc has a twelve month low of $8.25 and a twelve month high of $11.36. The business's fifty day simple moving average is $10.38 and its two-hundred day simple moving average is $9.95. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The firm has a market capitalization of $51.04 billion, a price-to-earnings ratio of 33.31, a P/E/G ratio of 2.82 and a beta of 0.24.

Haleon (NYSE:HLN - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The firm had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.38 billion. Analysts predict that Haleon plc will post 0.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on HLN shares. Wall Street Zen lowered shares of Haleon from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. BNP Paribas Exane raised shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price target on the stock in a report on Tuesday. HSBC reiterated a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Barclays reaffirmed an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Six investment analysts have rated the stock with a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Haleon presently has an average rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.